A Comparison of the COVID-19 Vaccinations Used During Various Time Periods in Iraq

Abstract

The sole means of preventing the COVID-19 pandemic are vaccines against the SARS-CoV2 virus (severe acute respiratory syndrome). By examining people's IgG levels and the times during which they survived at high levels, the study sought to evaluate the efficacy of the three vaccination types utilized in the Nineveh governorate. IgM appeared in 82.5% of the positive control samples and in 30% of the negative control samples, reflecting the presence of recent cases of infection in vaccine recipients after vaccination. IgM appeared in 46% of those who received the Sinopharm vaccine, 39.1% of those who received the Pfizer vaccine, and 13.9% of those who received the AstraZeneca vaccine. For the first time period following the immunization (less than 8 months) and for the three different vaccine types, the rate of IgG occurred at a high level. It was highest among individuals who received vaccines from Sinopharm, AstraZeneca, and Pfizer, and its rate started to fall as the amount of time passed after the shots for all three vaccine kinds. there are no obvious substantial differences, the rate of IgG appeared among individuals with a positive IgM at the highest level in the third time period when vaccinated with the Pfizer and Sinopharm vaccines, and in the second time period when vaccinated with the Astrazeneca vaccine. As its rate increased generally with the increase in the period of the vaccine, this reflects the role of post-vaccination infection. The body's IgG levels rise as a result of (IgM+).